🇺🇸 FDA
Patent

US 11712474

Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition

granted A61KA61K31/05A61K31/658

Quick answer

US patent 11712474 (Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition) held by Regen Biopharma, Inc. expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regen Biopharma, Inc.
Grant date
Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/05, A61K31/658, A61K31/7088, A61K31/7105